Drugs List

Therapeutic Indications

Uses

Meningococcal meningitis group B - prophylaxis

Administration

For intramuscular injection into the deltoid muscle.

Contraindications

Children under 10 years
Severe febrile conditions

Precautions and Warnings

Immunosuppression
Patients over 65 years
Breastfeeding
Coagulopathy
Immunodeficiency syndromes
Pregnancy
Thrombocytopenia

Postpone immunisation if there is active or suspected infection
Advise ability to drive/operate machinery may be affected by side effects
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Different brands may not be interchangeable
Do not mix with other vaccines in the same syringe
Do not use if solution is discoloured or particulates are apparent
Inject other vaccines at different sites
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Remain alert to possible coincidental meningitis
Follow national immunisation guidelines

Individuals with familial complement deficiencies or those receiving treatments that inhibit terminal complement activation are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B, even if they develop antibodies following vaccination.

Pregnancy and Lactation

Pregnancy

Use meningococcal group B (2-valent) vaccine with caution during pregnancy.

The manufacturer advises that the potential risk to for pregnant women is unknown and that the vaccine may be used when clinically indicated if there is a clear risk of exposure to meningococcal infection. At the time of writing there is limited published information regarding the use of meningococcal group B (2-valent) vaccine during pregnancy. Animal studies have not shown teratogenic effects.

Lactation

Use meningococcal group B (2-valent) vaccine with caution in breastfeeding.

The manufacturer advises meningococcal group B (2-valent) vaccine may be used during breastfeeding if benefits outweigh the risks. The presence of the vaccine in human breast milk and the effects on exposed infants is unknown.

Side Effects

Allergic reaction
Arthralgia
Chills
Diarrhoea
Erythema at injection site
Fatigue
Headache
Local pain (injection site)
Myalgia
Nausea
Pyrexia
Swelling (injection site)
Vomiting

Presentation

Vaccine containing protein from Neisseria meningitidis group B.

These products have been produced by recombinant technology using E.coli.

For comprehensive information or advice on this product or the immunisation programme in the UK, the following website should be accessed.

https://www.gov.uk/government/collections/immunisation-against-infectious-disease-the-green-book

Drugs List

Therapeutic Indications

Uses

Meningococcal meningitis group B - prophylaxis

Dosage

Adults

Children

Administration

For intramuscular injection into the deltoid muscle.

Contraindications

Children under 10 years
Severe febrile conditions

Precautions and Warnings

Immunosuppression
Patients over 65 years
Breastfeeding
Coagulopathy
Immunodeficiency syndromes
Pregnancy
Thrombocytopenia

Postpone immunisation if there is active or suspected infection
Advise ability to drive/operate machinery may be affected by side effects
Impaired response possible in immunocompromised patients
Vaccine may not be effective in 100% of patients
Different brands may not be interchangeable
Do not mix with other vaccines in the same syringe
Do not use if solution is discoloured or particulates are apparent
Inject other vaccines at different sites
Record name and batch number of administered product
Resuscitation facilities must be immediately available
Remain alert to possible coincidental meningitis
Follow national immunisation guidelines

Individuals with familial complement deficiencies or those receiving treatments that inhibit terminal complement activation are at increased risk for invasive disease caused by Neisseria meningitidis serogroup B, even if they develop antibodies following vaccination.

Pregnancy and Lactation

Pregnancy

Use meningococcal group B (2-valent) vaccine with caution during pregnancy.

The manufacturer advises that the potential risk to for pregnant women is unknown and that the vaccine may be used when clinically indicated if there is a clear risk of exposure to meningococcal infection. At the time of writing there is limited published information regarding the use of meningococcal group B (2-valent) vaccine during pregnancy. Animal studies have not shown teratogenic effects.

Lactation

Use meningococcal group B (2-valent) vaccine with caution in breastfeeding.

The manufacturer advises meningococcal group B (2-valent) vaccine may be used during breastfeeding if benefits outweigh the risks. The presence of the vaccine in human breast milk and the effects on exposed infants is unknown.

Side Effects

Allergic reaction
Arthralgia
Chills
Diarrhoea
Erythema at injection site
Fatigue
Headache
Local pain (injection site)
Myalgia
Nausea
Pyrexia
Swelling (injection site)
Vomiting

Overdosage

It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

The following number will direct the caller to the relevant local centre (0844) 892 0111

Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( www.toxbase.org ) or if this is unavailable at the backup site ( www.toxbasebackup.org ).

Further Information

Last Full Review Date: May 2019

Reference Sources

Summary of Product Characteristics: Trumenba. Pfizer Limited. Revised November 2018.

Immunisation against infectious diseases: 'The Green Book', Department of Health.
Available at: https://www.gov.uk/government/organisations/public-health-england/series/immunisation-against-infectious-disease-the-green-book
Last accessed: 08 May 2019.